StoneX Group’s Ensysce Biosciences ENSC Stock Holding History

StoneX Group’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4	Closed	-$2.75K	–	602
2022 Q3	$2.75K	Buy	4 +1	+33%	+$1.63K	﹤0.01%	332
2022 Q2	$10.3K	Buy	+3	New	+$8.4K	﹤0.01%	462

Other funds holding ENSC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

StoneX Group's ENSC Position: Q4 2022 in Review

StoneX Group sold out of Ensysce Biosciences (ENSC) in Q4 2022, closing a stake of 4 shares — an estimated $2.75K sold.

StoneX Group first reported a position in ENSC in Q2 2022 and held it in 2 quarters. The position peaked at $10.3K in Q2 2022. 13 funds tracked by Wall St. Rank hold ENSC as of Q4 2022.

StoneX Group reported no remaining Ensysce Biosciences position as of Q4 2022 after selling out during the quarter.
StoneX Group sold 4 Ensysce Biosciences shares in Q4 2022, an estimated $2.75K.
StoneX Group first reported a position in Ensysce Biosciences in Q2 2022 and held it in 2 quarters.
StoneX Group's Ensysce Biosciences position peaked at $10.3K in Q2 2022.
13 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.